MG-132

Catalog No.S2619

MG-132 Chemical Structure

Molecular Weight(MW): 475.62

MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.

Size Price Stock Quantity  
USD 50 In stock
USD 170 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's MG-132 had a noticeably greater effect when compared with similar products from Sigma: This is directly due to using the (S, R, S) - (-) - 2 configuration.

P21 protein can be degraded through ubiquitylation pathway. Inhibition of proteasome activities results in the accumulation of P21 protein, therefore, the more powerful the inhibiting effect, the more P21 protein is accumulated. (testing protein: P21; Cell line: Hela; treatment condition: final concentration of MG-132 is 5μM, with a 6 hour treatment time)

Cited by 1040 Publications

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.
Targets
Proteasome [9]
(Cell-free assay)
100 nM
In vitro

MG-132 displays >1000 times more activity than ZLLal in inhibiting the ZLLL-MCA-degrading activity of 20S proteasome with IC50 of 100 nM versus 110 μM. MG-132 also inhibits calpain with IC50 of 1.2 μM. MG-132 induces neurite outgrowth in PC12 cells at an optimal concentration of 20 nM, displaying 500 times more potency than ZLLal. [1] MG-132 (10 μM) potently inhibits TNF-α-induced NF-κB activation, interleukin-8 (IL-8) gene transcription, and IL-8 protein release in A549 cells by inhibition of proteasome-mediated IκBα degradation. [2] MG-132 treatment potently induces p53-dependent apoptosis in KIM-2 cells by 26S proteasome inhibition. [3] Unlike BzLLLCOCHO or PS-341, MG-132 treatment results in weak inhibition of the chymotrypsinlike (CT-L) and peptidylglutamyl peptide hydrolysing (PGPH) activities of the 26S proteasome, whereas multiple myeloma cells (U266 and OPM-2) are more sensitive to induction of apoptosis by MG-132 than BzLLLCOCHO. [4] MG-132 (1 μM) sensitizes TRAIL-resistant prostate cancer cells by activating the AP-1 family members c-Fos and c-Jun, which, in turn, repress the antiapoptotic molecule c-FLIP(L). [5] MG-132 significantly enhances the ability of inositol hexakisphosphate (IP6) to reduce cellular metabolic activity in both PC3 and DU145 androgen-independent prostate cancer (AIPCa) cell lines. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LPS-stimulated RAW264.7 cells NUL6XIJiTnWwY4Tpc44hSXO|YYm= NInpNG0zPSEQvF2= NE[wPYNFVVOR MYXJcohq[mm2czDubZRzcWNib4jp[IUheHKxZIXjeIlwdiC5aYToJGlEPTBib3[gNE4yKM7:TR?= MWKyOFY6PzR7Nh?=
HL-60 NVHJOo5xS3m2b4TvfIlkKEG|c3H5 NHfNSXA1OCEQvF2= MWG0PEBp MX\EUXNQ M17WT2lEPTB:MUCg{txO NWHUWmY1OjR4OUe0PVY>
SMMC-7721 NH6xbIZEgXSxdH;4bYMhSXO|YYm= MUK0NEDPxE1? MkXtOFghcA>? NVfPSXltTE2VTx?= M2jQS2lEPTB;Nz6xJO69VQ>? NFfqPJAzPDZ7N{S5Oi=>
A-549 MkSxR5l1d3SxeHnjJGF{e2G7 M1\Yc|QxKM7:TR?= NVzUOVBpPDhiaB?= NFrhN3VFVVOR M2C4ZWlEPTB:MUCg{txO NFXpUZgzPDZ7N{S5Oi=>
MCF-7 M3XFcGN6fG:2b4jpZ{BCe3OjeR?= MXe0NEDPxE1? MkTuOFghcA>? NILROoVFVVOR M{TpdWlEPTB;Nz6zJO69VQ>? MV2yOFY6PzR7Nh?=
SW-480 NGnZXXFEgXSxdH;4bYMhSXO|YYm= MmfFOFAh|ryP NYrEUphTPDhiaB?= MlXHSG1UVw>? MVjJR|UxRTRizszN MlnsNlQ3QTd2OU[=
NCI-H929 NWDDXVAyS3m2b4TvfIlkKEG|c3H5 NGG2VGMyKM7:TR?= NVvV[llVPzJiaB?= MVzEUXNQ Ml\sTWM2OD1yLkG3JO69VQ>? NIiwSXQzPDZ{NUC4PC=>
293T M2TBcmN6fG:2b4jpZ{BCe3OjeR?= NX3aVm1ZOTBizszN NGLJd4Y4OiCq M3\pZmROW09? MlvVTWM2ODx{IN88US=> NEL6UW0zPDZ{NUC4PC=>
293T MXrGeY5kfGmxbjDBd5NigQ>? NY\Pc49IOTBizszN NVG0[VR5OjRiaB?= NGfBV29FVVOR MmjzUY9l\XKjdHXsfUBqdmS3Y3XzJIhm[XRvc3jvZ4shKA>? NGXiSXkzPDZ{NUC4PC=>
HeLa MmLJT4lv[XOnIFHzd4F6 MlzKNVAh|ryP M2KyR|EhcA>? M4nnOmROW09? MoXMTY5lfWOnczDQRXJRKGOuZXH2ZYdmKGK7IHnubIljcXSrbnegdJJwe2Wjc3;t[UBi[3Srdnn0fS=> M3[1fFI1OzJzOEOz
MDA-MB-231 NHntcVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXT2SVNGOSEQvF2= M3XIV|czKGh? M4ixdmROW09? M2LScWlEPTB;MD6xPEDPxE1? NUjtN3FKOjRzNUOyNFY>
MCF-7 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzhb5UyKM7:TR?= MmXvO|IhcA>? MXPEUXNQ NWO5fWlCUUN3ME2wMlE{KM7:TR?= M{LPWVI1OTV|MkC2
MCF10A NYC3Z|JCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PqTFEh|ryP MVe3NkBp NUDvenVXTE2VTx?= MYfJR|UxRTBwMkmg{txO NGToZnozPDF3M{KwOi=>
HEK-293 NVGxc|dSU2mwYYPlJGF{e2G7 MkDiNkBidmRiMkCg{txO NF:3bVMzKGh? NG\4endFVVOR NH3XfGRKdmirYnn0d{BEcFRvTDDhZ5Rqfmm2eTD3bZRpKEmFNUCgc4YhQSCwTTC= MXKyN|U1ODd7MB?=
Calu6 Mn;VSpVv[3Srb36gRZN{[Xl? NXW4fY5nOTBizszN Ml7jNVghcA>? Mne0SG1UVw>? MXHTbYdvcW[rY3HueIx6KGGlY4XteYxifGW|IH\yZZRigGmwIIDy[YN2enOxch?= M1i1fVI{PTB4NEi2
IFN-gamma-induced RAW264.7 MWnGeY5kfGmxbjDBd5NigQ>? NFe4dHdFVVOR NHnq[VdKdmirYnn0d{BvcXS{aXOgc5hq\GVicILv[JVkfGmxbjD3bZRpKEmFNUCgc4YhOC5yN{eg{txO M2jjSlIzOjd5Mke3
IPC227F Ml\iR5l1d3SxeHnjJGF{e2G7 NFq0W24yKM7:TR?= MYm0PEBp MmnTSG1UVw>? NXjwOHVKUUN3ME2wMlA4PyEQvF2= MV:yNVkzPDV{OB?=
Hepa-1c1c7 NUG2NHlUTnWwY4Tpc44hSXO|YYm= MV2yOUDPxE1? NHH6[oY3KGh? NU[wWo0xTE2VTx?= NHL5[GRKdmO{ZXHz[ZMhVnKoMjDwdo91\WmwIHzleoVt MYqyNFM6OjV2NB?=
COS-7 M3G5N2N6fG:2b4jpZ{BCe3OjeR?= MkjrNVAh|ryP NY\KTGJkTE2VTx?= MUHJR|UxRDFyIN88US=> NYrBZW1tOThyOEiwPVc>
HuH-7 NGX4WVdEgXSxdH;4bYMhSXO|YYm= NXfNdpRZOTBizszN M1[3SWROW09? MX7JR|UxRDFyIN88US=> MUWxPFA5QDB7Nx?=
OCI-Ly3 NVXtO|J2TnWwY4Tpc44hSXO|YYm= NWPJOm4zOTBizszNxsA> M3ztW|QhcA>? MlyzSG1UVw>? Ml33TY5lfWOnczDoeY1idiCLa3HwdIFD[WyyaHGgd5Ri[mmuaYrheIlwdiC5aYToJGVEPTBib3[gNUDPxE1? MYKxPFAzPDFzMx?=
A2780 cDDP MlmxRZBweHSxc3nzJGF{e2G7 NHXXdHYzPCCq MWHEUXNQ NH:xRWpKdmS3Y3XzJIFxd3C2b4Ppd{BjgSCrbnjpZol1cW6pIGDUSW4h\GWpcnHkZZRqd25? NWrueVFIOTd4OESwNVg>
LPS-stimulated RAW264.7 cells NIjrXmxHfW6ldHnvckBCe3OjeR?= NHr0[XdFVVOR MluwTY5pcWKrdIOgUmYuc2GycHHCJGRPSSCkaX7kbY5o NFrFNo0yPzRyN{K3Oy=>
PC12 M4PVdGZ2dmO2aX;uJGF{e2G7 M2H3b|ExOCEQvF5CpC=> NIPTPVgzPCCq M2X6TWROW09? NFq5fWZKdmirYnn0d{A3NU:KRFGtJIFv\CCKMl:yMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 MUCxO|E2QDR3NB?=
PC3 M3PS[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjQZ5BLOjBizszN MWq0PEBp NUTsU4lwTE2VTx?= MUDJR|UxRTBwNjFOwG0> MnLRNVY3QDZ3M{e=
LP-1 NV3qWYo1SXCxcITvd4l{KEG|c3H5 NITyOng{ODBibl2= NHzqR24zPCCq M3\RdWROW09? NFXsVXpKdmS3Y3XzJIFxd3C2b4Ppd{BjgSCrbnPy[YF{cW6pIHPs[YF3\WRiUFHSVEBt\X[nbDDhcoQhemWmdXPpcochVWOuLUGgdJJwfGWrbjDs[ZZmdA>? NX6w[3pKOTV7NUi1PFk>
ES6 M13QT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TPdmlEPTB;MD6wNVMxPiEQvF2= NI\ieXdUSU6JRWK=
A101D M3jDRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEOxNFdKSzVyPUCuNFMzPzlizszN NXfQU5k4W0GQR1XS
OCUB-M MmDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rLVWlEPTB;MD6wN|c{PyEQvF2= MUjTRW5ITVJ?
LB2518-MEL NWPNNZFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTBwMEO3OkDPxE1? NV\4bpFqW0GQR1XS
SH-4 NVu0Wnd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYSxfndQUUN3ME2wMlA1OzFizszN NEfHbY9USU6JRWK=
KNS-42 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkG3TWM2OD1yLkC0OFQyKM7:TR?= MVrTRW5ITVJ?
DSH1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\EOopKSzVyPUCuNFUzQDlizszN MnnLV2FPT0WU
NTERA-S-cl-D1 NVnyZndbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rnb2lEPTB;MD6wOVc4OiEQvF2= NF[xNYdUSU6JRWK=
D-542MG NX;ESXJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojITWM2OD1yLkC1PVU4KM7:TR?= MX3TRW5ITVJ?
KS-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTBwME[0OVgh|ryP MkexV2FPT0WU
BL-41 M4KzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrRTWM2OD1yLkC2PVQ4KM7:TR?= NYmyfnpkW0GQR1XS
LXF-289 M{\IcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnoc2lKSzVyPUCuNFcxPjZizszN Mo\SV2FPT0WU
D-247MG NXXKNYgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwMEeyNFkh|ryP MYDTRW5ITVJ?
MMAC-SF MnXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfjSIpKSzVyPUCuNFczPjhizszN MWHTRW5ITVJ?
CP66-MEL NFnZV4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVv4U2VMUUN3ME2wMlA4PSEQvF2= MlfrV2FPT0WU
LB771-HNC NFv3UlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwMEiwN|Yh|ryP NFvHZ3VUSU6JRWK=
no-10 NFLkOWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVm1XVlmUUN3ME2wMlA5QTB7IN88US=> NEnHRVdUSU6JRWK=
A388 M4rJSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fqPGlEPTB;MD6wPVA3PSEQvF2= MVfTRW5ITVJ?
OPM-2 MoHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XvUWlEPTB;MD6xNFQ4PCEQvF2= M{fubnNCVkeHUh?=
OVCAR-4 NXjiTphYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwMUC5N|gh|ryP MnXFV2FPT0WU
HOP-62 MoTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnoTWM2OD1yLkGwPVQ6KM7:TR?= NHn2VXpUSU6JRWK=
ML-2 M3rxN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXXRmY1UUN3ME2wMlEyQDB4IN88US=> Mm\OV2FPT0WU
UACC-257 NGryd2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTBwMUG5Nlch|ryP MmrxV2FPT0WU
NEC8 Mn7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMUG5PVUh|ryP NWPHXZV7W0GQR1XS
ONS-76 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvHTWM2OD1yLkGyPVM2KM7:TR?= MWnTRW5ITVJ?
KE-37 NYrmR2JTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDnfndNUUN3ME2wMlE{Ojd6IN88US=> MX;TRW5ITVJ?
HT-144 MkPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;POWlEPTB;MD6xN|g6PSEQvF2= MUXTRW5ITVJ?
LB2241-RCC MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LTUmlEPTB;MD6xOFI1PyEQvF2= M2riR3NCVkeHUh?=
TE-5 NWPoTFBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;oR21KSzVyPUCuNVQzPzhizszN M4HDVnNCVkeHUh?=
KINGS-1 M2nofGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTBwMUS3PUDPxE1? Mmn2V2FPT0WU
NCI-H69 NH3KVlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7aenRkUUN3ME2wMlE2OTRzIN88US=> NGfIWphUSU6JRWK=
CAS-1 NEnze4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfWTWM2OD1yLkG1OFgzKM7:TR?= NXPiSpBsW0GQR1XS
D-263MG NWj2U|RKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVL1bnlTUUN3ME2wMlE3ODB4IN88US=> NGnBb3VUSU6JRWK=
A253 NUD5ZZdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwMU[xNlgh|ryP MW\TRW5ITVJ?
PF-382 NEC3SWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XpV2lEPTB;MD6xOlcxPiEQvF2= NVOxd41pW0GQR1XS
CESS Ml;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7zc3lnUUN3ME2wMlE4ODZizszN NX;YUJlOW0GQR1XS
MZ2-MEL NUPhWIZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mof5TWM2OD1yLkG3OVU6KM7:TR?= M2\FfnNCVkeHUh?=
HEL NYjvWYoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwMUi1NVch|ryP M13Db3NCVkeHUh?=
D-392MG MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTBwMUmxNVUh|ryP Mn\NV2FPT0WU
SK-LMS-1 NVXud5I4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfFTWM2OD1yLkG5N|A{KM7:TR?= MWPTRW5ITVJ?
GI-ME-N MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHTTWM2OD1yLkG5N|A3KM7:TR?= M4jTOXNCVkeHUh?=
LB831-BLC NVX3blcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmf2TWM2OD1yLkG5N|Qh|ryP MYTTRW5ITVJ?
DU-4475 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFn4d5JKSzVyPUCuNVk3PThizszN M4nzZ3NCVkeHUh?=
IST-SL1 NFLRZVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;FTWM2OD1yLkKwNFk1KM7:TR?= MoC5V2FPT0WU
GAK MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLNWXJKSzVyPUCuNlA2OzRizszN NWDoWoRTW0GQR1XS
EW-1 M{TaXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4O1U2lEPTB;MD6yNVA1PyEQvF2= NWjpNYRSW0GQR1XS
LAMA-84 MkDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXETWM2OD1yLkKxPFUyKM7:TR?= NV\0TWVLW0GQR1XS
SK-UT-1 NHXTS4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTBwMkKwOFkh|ryP M1rDUXNCVkeHUh?=
VA-ES-BJ MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDmTWM2OD1yLkKyNlU4KM7:TR?= MkXMV2FPT0WU
ACN NHX3VIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfYU5VKSzVyPUCuNlI3OzhizszN MnywV2FPT0WU
SK-PN-DW M2\idGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HjOmlEPTB;MD6yN|E6KM7:TR?= NX;KfFR1W0GQR1XS
HD-MY-Z MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGf4UnZKSzVyPUCuNlM{ODNizszN NID6RZNUSU6JRWK=
LB373-MEL-D M1;ZZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwMkSxPVgh|ryP NUTQbWQyW0GQR1XS
COLO-829 NWnwdmgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jxPGlEPTB;MD6yOFI2PyEQvF2= M1;TZnNCVkeHUh?=
ES8 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXUTWM2OD1yLkK0O|Y{KM7:TR?= MkeyV2FPT0WU
RXF393 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTBwMkWwNVUh|ryP MXTTRW5ITVJ?
TK10 NV3zPGJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXK2S|dEUUN3ME2wMlI2PDN3IN88US=> MXrTRW5ITVJ?
LOUCY Mm\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDp[lRTUUN3ME2wMlI2PDV4IN88US=> M3zrOXNCVkeHUh?=
MZ7-mel MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HWfmlEPTB;MD6yOlM4PCEQvF2= NUSwNHltW0GQR1XS
CP67-MEL NYXtT2ZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3j4c2lEPTB;MD6yOlc{KM7:TR?= NEDvOnBUSU6JRWK=
C2BBe1 NYj2c25VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzQTWM2OD1yLkK3PVA4KM7:TR?= M3TudXNCVkeHUh?=
K052 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7HRYZQUUN3ME2wMlI5QTlizszN MkDxV2FPT0WU
MOLT-16 NXTGV4Y{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwMkm1NlQh|ryP MoPSV2FPT0WU
KNS-81-FD MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvMTWM2OD1yLkOwN|I{KM7:TR?= MXLTRW5ITVJ?
CMK M{\JdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnGNJZKSzVyPUCuN|EyOiEQvF2= M3fEUXNCVkeHUh?=
LAN-6 NH2zbZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTBwM{GzJO69VQ>? MlS0V2FPT0WU
KLE M4DjNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTwZ45KSzVyPUCuN|E{ODZizszN MWXTRW5ITVJ?
NCCIT NWPSdmpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvnTWM2OD1yLkOxO|g{KM7:TR?= MWPTRW5ITVJ?
HH NUXNfm06T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\5[INKSzVyPUCuN|I5QTdizszN M4fF[HNCVkeHUh?=
TE-8 M2T3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nncmlEPTB;MD6zOFI4QSEQvF2= NGnEZ45USU6JRWK=
GDM-1 M3fVS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7XTWM2OD1yLkO1NVA1KM7:TR?= MWnTRW5ITVJ?
NCI-H747 M2[zT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jKXGlEPTB;MD6zO|ExOyEQvF2= MmLUV2FPT0WU
NCI-H1092 NWPvR5l1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{W5e2lEPTB;MD6zPFg1PCEQvF2= Mn[zV2FPT0WU
8-MG-BA Mn;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;YdYRKSzVyPUCuN|k5OzdizszN NVXOVIpRW0GQR1XS
NB17 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwNEK5O{DPxE1? NHPGe4pUSU6JRWK=
LC4-1 NFPPV4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHzTWM2OD1yLkSzOlA4KM7:TR?= NFrTc2FUSU6JRWK=
TE-1 NUXlNphoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{f3XGlEPTB;MD60OVEyQSEQvF2= NHj0S2pUSU6JRWK=
KALS-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwNE[1PFQh|ryP NFLBTFFUSU6JRWK=
CCRF-CEM MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrXR2tKSzVyPUCuOFc3PzRizszN M2LwbHNCVkeHUh?=
OS-RC-2 MkPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3YTWM2OD1yLkS3PVczKM7:TR?= MYjTRW5ITVJ?
A704 MnXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrvTWM2OD1yLkS4OlkzKM7:TR?= MYTTRW5ITVJ?
BB49-HNC MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTkUm92UUN3ME2wMlQ6ODl4IN88US=> MYHTRW5ITVJ?
EVSA-T M1[0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3XTWM2OD1yLkS5PVEyKM7:TR?= NX\K[IJMW0GQR1XS
Mo-T M3LNWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwNUG3OlIh|ryP Ml[2V2FPT0WU
MONO-MAC-6 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTkbVFKSzVyPUCuOVM3OTFizszN MnPlV2FPT0WU
BB65-RCC Mkn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjH[JdKSzVyPUCuOVY5OTFizszN NGfwUHJUSU6JRWK=
NCI-H1882 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTBwNUmwN|Yh|ryP NFrzVm5USU6JRWK=
TE-9 NGrOdYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTBwNkGwN|Mh|ryP NI\pcGFUSU6JRWK=
NCI-H2126 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;TVIdjUUN3ME2wMlYzPjZ7IN88US=> NHTqd3VUSU6JRWK=
SF268 MkX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTTTWM2OD1yLk[1OlQyKM7:TR?= NHPISY9USU6JRWK=
SW872 NEfDNIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkK0TWM2OD1yLk[1O|I6KM7:TR?= NIixfJVUSU6JRWK=
LS-513 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nsbmlEPTB;MD62Olc2OSEQvF2= M1jL[HNCVkeHUh?=
NCI-H1355 MlLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmm1TWM2OD1yLk[4OlE6KM7:TR?= M1m2RXNCVkeHUh?=
BL-70 M3W1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXQVWlKSzVyPUCuOlk{QDhizszN NIXkVnBUSU6JRWK=
NCI-SNU-5 M4rRbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPOcnBKSzVyPUCuOlk2PDVizszN NEm2ZotUSU6JRWK=
SNU-C2B M17nO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PncWlEPTB;MD63NFc{QSEQvF2= NIXpXFdUSU6JRWK=
GB-1 NUX0NnpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfqeWIxUUN3ME2wMlczOTJ2IN88US=> NEfofYVUSU6JRWK=
CTB-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTBwN{e5OVUh|ryP MlW5V2FPT0WU
Becker NITIe|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwN{m2NlEh|ryP NETKUW9USU6JRWK=
KM12 M2rKcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWG4UphUUUN3ME2wMlg2PDZ4IN88US=> NEn4SHZUSU6JRWK=
ES7 NHHPOXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7lS2VKSzVyPUCuPFk3PSEQvF2= MYTTRW5ITVJ?
COLO-684 Ml7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTBwOUC2OVgh|ryP Mkj5V2FPT0WU
HCC2998 M{LZTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jaeWlEPTB;MD65N|g2PCEQvF2= NHrjXmdUSU6JRWK=
TE-10 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITqUm1KSzVyPUCuPVY1OyEQvF2= Mn7YV2FPT0WU
SF126 MnH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnQTWM2OD1yLkm4PVcyKM7:TR?= MnLWV2FPT0WU
EKVX M4LmNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1yxeGlEPTB;MT6wN|Q1OiEQvF2= MUfTRW5ITVJ?
KARPAS-45 NUfmZnpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3xOpgzUUN3ME2xMlA1ODF4IN88US=> M2PHTnNCVkeHUh?=
KGN NWP6c5ZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTFwMEWwOFUh|ryP Ml[yV2FPT0WU
ES1 M2L1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDITWM2OD1zLkC3PVIyKM7:TR?= M2D1ZXNCVkeHUh?=
L-540 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWr6[mNSUUN3ME2xMlEyQDN7IN88US=> MYDTRW5ITVJ?
KURAMOCHI MoLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV35fmxDUUN3ME2xMlEzOzd2IN88US=> MlH6V2FPT0WU
LU-65 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\neI9rUUN3ME2xMlEzPzV|IN88US=> NYjZNYNGW0GQR1XS
MFH-ino MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHv[4dJUUN3ME2xMlE4PTBzIN88US=> M1zscnNCVkeHUh?=
NCI-H23 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vWfmlEPTB;MT6yNFQyKM7:TR?= MWPTRW5ITVJ?
IA-LM MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTwTWM2OD1zLkK0NVE3KM7:TR?= MYDTRW5ITVJ?
PSN1 M2i2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3YZVFMUUN3ME2xMlI4ODF4IN88US=> MWDTRW5ITVJ?
NCI-H719 MkDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rPVmlEPTB;MT6yO|QyOSEQvF2= MVzTRW5ITVJ?
SW684 NGnwO3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PXS2lEPTB;MT6yPFY2QSEQvF2= MlfxV2FPT0WU
HCE-4 NGHiTXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTFwM{CyNlEh|ryP M1u5W3NCVkeHUh?=
EW-16 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\5dYVKSzVyPUGuN|E{PDdizszN M1zQR3NCVkeHUh?=
NCI-H128 NYDNTFNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTFwM{W4NVQh|ryP M2fnZ3NCVkeHUh?=
HC-1 NH[ySYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\0fJBKSzVyPUGuN|gyPyEQvF2= M{fU[3NCVkeHUh?=
IST-MES1 NF7Jd5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnj2TWM2OD1zLkSwNlA5KM7:TR?= MY\TRW5ITVJ?
Raji MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LGSmlEPTB;MT60NVg2KM7:TR?= NIDhWGdUSU6JRWK=
DMS-114 NF25V|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDQTWM2OD1zLkS0OVM6KM7:TR?= NIjv[ZlUSU6JRWK=
GI-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfKTWM2OD1zLkS3NVMyKM7:TR?= MUPTRW5ITVJ?
NCI-H2081 NFr6cldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPnTWM2OD1zLkW1NVk3KM7:TR?= Mo\DV2FPT0WU
LC-1F MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTFwNUWxPVgh|ryP NXXzZZc1W0GQR1XS
NCI-H2227 MoP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NES3copKSzVyPUGuOlE2PjFizszN MYXTRW5ITVJ?
D-502MG NGnVd2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTFwNkeyNVEh|ryP MoPEV2FPT0WU
NCI-H2141 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LPfWlEPTB;MT62O|MyPyEQvF2= MmfFV2FPT0WU
LS-411N MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTFwNkm4NFch|ryP NWPGbWg1W0GQR1XS
SU-DHL-1 NIfGd|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmiyTWM2OD1zLkexNlgyKM7:TR?= MWrTRW5ITVJ?
BB30-HNC NYT0bHZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\QcotqUUN3ME2xMlczPjh3IN88US=> NYDwdFFMW0GQR1XS
TE-15 MlK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLQTWM2OD1zLkmyN|c{KM7:TR?= NGX5UIFUSU6JRWK=
JVM-3 MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTRTWM2OD1zLkmzPVA1KM7:TR?= NUPheI5lW0GQR1XS
IST-SL2 NUnYToVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnr2TWM2OD1{LkCxNlUzKM7:TR?= MYDTRW5ITVJ?
EW-18 M2PTWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGn3fpFKSzVyPUKuNFI{OzdizszN MX\TRW5ITVJ?
DJM-1 M{DvPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTJwMEK1OVIh|ryP MXPTRW5ITVJ?
no-11 NEXCcXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTJwMEOxNFQh|ryP MYfTRW5ITVJ?
QIMR-WIL NIPm[nNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfBTWM2OD1{LkG2O|YzKM7:TR?= M1XmNnNCVkeHUh?=
MC-CAR M4jpcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTJwMkK5OUDPxE1? NEDvUXFUSU6JRWK=
KM-H2 M{KySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTxbnl[UUN3ME2yMlI6ODR|IN88US=> M4PsO3NCVkeHUh?=
ECC12 NEXtXmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPWd5lkUUN3ME2yMlM4QTRizszN NY\JXlQ3W0GQR1XS
HCE-T M{[0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELOeGNKSzVyPUKuOFQ5QDNizszN M{HqR3NCVkeHUh?=
MFM-223 NIfVfmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4CyUWlEPTB;Mj61NFg4OSEQvF2= M1vYUXNCVkeHUh?=
SW982 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXab2pKSzVyPUKuOVE1QCEQvF2= MUTTRW5ITVJ?
KG-1 M{f5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfYdI5KSzVyPUKuPFg4QTFizszN MlyxV2FPT0WU
ES4 M2TPbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfx[4U2UUN3ME2zMlA3OTFzIN88US=> MYHTRW5ITVJ?
SCC-3 Mn\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDkdmFKSzVyPUOuNVA5PDhizszN MYjTRW5ITVJ?
RH-1 NGXmOXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4H0[2lEPTB;Mz6zPFc1QCEQvF2= NF7UR4RUSU6JRWK=
NCI-H748 NV7VRnByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;nTWM2OD1|LkS0NlY3KM7:TR?= MkPrV2FPT0WU
HCC2218 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLJb2tKSzVyPUOuOFY6OzdizszN NILvfZhUSU6JRWK=
MEG-01 NFjnZWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;VSWlEPTB;Mz61PVY5KM7:TR?= NIn4fIlUSU6JRWK=
NB12 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLOd5FKSzVyPUOuOVk5QDhizszN MmWwV2FPT0WU
SNB75 MkjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3xTWM2OD1|Lk[wNVA{KM7:TR?= Mmn0V2FPT0WU
KMS-12-PE MlmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmexTWM2OD1|Lk[3O|I{KM7:TR?= NVjBcmhzW0GQR1XS
SKM-1 M3TvfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnzT3Z5UUN3ME2zMlcyOzd4IN88US=> NYTxcVhYW0GQR1XS
COLO-320-HSR NFe0OppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTNwN{W2N|Qh|ryP MWLTRW5ITVJ?
NKM-1 NWfzVXh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDTVXFKSzVyPUOuO|c{PzhizszN MYPTRW5ITVJ?
TE-6 NITZeYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTNwOUS1OlEh|ryP MVTTRW5ITVJ?
D-336MG MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnj5TWM2OD12LkCxNVY3KM7:TR?= NVryNoJoW0GQR1XS
NCI-H1650 MnnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPxU2ZKSzVyPUSuNVU4QTdizszN Mn7SV2FPT0WU
ES3 M1vuOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTRwM{K4NlQh|ryP MYrTRW5ITVJ?
YT MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrwfodKSzVyPUSuN|U1OjRizszN MUjTRW5ITVJ?
ES5 NH;nb4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTRwNECyOVUh|ryP NF\1O5lUSU6JRWK=
LB647-SCLC NVTYPZQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnK2TWM2OD12LkW2N|A5KM7:TR?= NInvS5dUSU6JRWK=
HAL-01 NV3kN3QzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPwTWM2OD12LkW3NFM1KM7:TR?= MnrBV2FPT0WU
LP-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\Ce|dKSzVyPUSuO|I{PzFizszN Mnm5V2FPT0WU
BC-1 MmrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M36zUGlEPTB;NT6wNFQ1PyEQvF2= NUDEO3MyW0GQR1XS
EB-3 M37GdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTVwMEOwOFEh|ryP Mme3V2FPT0WU
GT3TKB Ml\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTVwMUe2OlIh|ryP MYnTRW5ITVJ?
NCI-H209 M1LHSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTVwMUmzOVIh|ryP NITld3lUSU6JRWK=
BT-474 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTvTWM2OD13LkKzNVAzKM7:TR?= NWXDSHF7W0GQR1XS
RKO M13TVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTVwMkO0NlIh|ryP MWPTRW5ITVJ?
SIMA MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPTTWM2OD13LkOwO|Y2KM7:TR?= MmPuV2FPT0WU
RL NUTDNVJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTVwM{e1OFEh|ryP NFLaNGhUSU6JRWK=
GCIY NVizbmtTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVWycXRpUUN3ME21MlQ4OjN4IN88US=> MnjmV2FPT0WU
Calu-6 MonGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rvU2lEPTB;NT62NlIh|ryP MlfuV2FPT0WU
ALL-PO MlHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnv2TWM2OD13Lk[zO|k2KM7:TR?= MVjTRW5ITVJ?
ARH-77 MoLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTVwNkewPFch|ryP MXfTRW5ITVJ?
A4-Fuk NXH4PYw5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XKRWlEPTB;Nj6wPFEyQCEQvF2= MmTUV2FPT0WU
NCI-H1581 M1:0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTZwMkO4OFkh|ryP MYnTRW5ITVJ?
HUTU-80 M2LL[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXNTWM2OD14LkO2PFk4KM7:TR?= MYfTRW5ITVJ?
TGW NHHlU|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPEVGhJUUN3ME22MlQ2PTl|IN88US=> M1HzZXNCVkeHUh?=
SK-N-FI NGHVUlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LidWlEPTB;Nj60OVg2PCEQvF2= M1vIUnNCVkeHUh?=
U-266 M4KwO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYn4c3k5UUN3ME22MlUyQTJ4IN88US=> M1zNVnNCVkeHUh?=
EM-2 NVfCZlA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2G3PGlEPTB;Nj62O|A6QSEQvF2= NGLUUJhUSU6JRWK=
NMC-G1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTZSZFOUUN3ME22MlcyQDl3IN88US=> M3vKWXNCVkeHUh?=
KASUMI-1 Mly5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Phb2lEPTB;Nj64OFc5PyEQvF2= MWjTRW5ITVJ?
NALM-6 NFPXcZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTZwOE[3OVQh|ryP NF6xXW5USU6JRWK=
OCI-AML2 MoLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33neGlEPTB;Nz6wNFMzPiEQvF2= M1v5TnNCVkeHUh?=
SHP-77 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLFWIZEUUN3ME23MlIzPDNizszN NGnLcnVUSU6JRWK=
NOMO-1 NX\oW5d6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7Fd4xOUUN3ME23MlI1OjV2IN88US=> NIrOWpFUSU6JRWK=
SK-N-DZ M3\GbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mle1TWM2OD15LkexNFg6KM7:TR?= M4nofXNCVkeHUh?=
LB1047-RCC NIfaXmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TqZWlEPTB;Nz63NlI{OSEQvF2= MWfTRW5ITVJ?
MZ1-PC MmK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTdwOE[1OVgh|ryP MWXTRW5ITVJ?
NB10 M1jmbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFGx[HdKSzVyPUeuPVk2PTZizszN NVLMeo1DW0GQR1XS
RL95-2 NITvdGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXv6[4RWUUN3ME24MlExQDR{IN88US=> NWPL[nZnW0GQR1XS
OMC-1 NEfBXopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLuXodYUUN3ME24MlUzOTlzIN88US=> NHWyPGhUSU6JRWK=
D-283MED Mn22S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDBTWM2OD16LkmxO|E6KM7:TR?= MkXNV2FPT0WU
MC116 NUXTXlE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmL0TWM2OD16Lkm3PVQh|ryP NHexb5ZUSU6JRWK=
SJSA-1 MnuyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTlwMEmwPVEh|ryP NYTMcVNZW0GQR1XS
JiyoyeP-2003 MlfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\xTWM2OD17LkK5N|E4KM7:TR?= MXHTRW5ITVJ?
IST-MEL1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4C2cmlEPTB;OT63OFE6QCEQvF2= M2jWXXNCVkeHUh?=
CTV-1 M2DBUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTFyLkC5O|kh|ryP NIj4e3VUSU6JRWK=
NH-12 NF[2THZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTFyLkK0N|Mh|ryP NYr0S|ZWW0GQR1XS
CA46 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTFyLkO2NUDPxE1? NIn3dHlUSU6JRWK=
NCI-SNU-1 Mmm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrZTWM2OD1zMD60PVY6KM7:TR?= NYfHbIptW0GQR1XS
SCLC-21H M1W4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPpWlFKSzVyPUGwMlY2QTZizszN M3TWdHNCVkeHUh?=
EC-GI-10 M3XJbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rkOWlEPTB;MUCuO|A{OSEQvF2= MXfTRW5ITVJ?
SR M4PpS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTFzLkCxPFUh|ryP MnHiV2FPT0WU
NCI-H1648 M4OyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HZUmlEPTB;MUGuNFk3PSEQvF2= M3;SXnNCVkeHUh?=
TGBC1TKB MkTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonQTWM2OD1zMT60NVAzKM7:TR?= M2TNdHNCVkeHUh?=
EW-11 MnLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTFzLkWxPFYh|ryP M132V3NCVkeHUh?=
SK-MM-2 NFnKXFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nRfWlEPTB;MUGuPFA3OSEQvF2= M3\Mc3NCVkeHUh?=
NCI-H524 NWjB[2ZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGKxblRKSzVyPUGxMlk5OjJizszN NFT1dIxUSU6JRWK=
NOS-1 NVLhW4hRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTF{LkCzOFUh|ryP MUTTRW5ITVJ?
AM-38 Mo\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzxNFBEUUN3ME2xNk42PjN|IN88US=> MXXTRW5ITVJ?
A498 M4XSc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPy[3RTUUN3ME2xNk44ODZ7IN88US=> M2jFZnNCVkeHUh?=
KARPAS-422 NU\QbVdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDFTWM2OD1zMj63OFk3KM7:TR?= MmHiV2FPT0WU
LU-139 MkPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTF{LkmwNlYh|ryP NETveW5USU6JRWK=
COR-L88 MmSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTF{LkmzPFIh|ryP NGHGcJhUSU6JRWK=
K5 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTF{Lkm0OlIh|ryP M1nwVXNCVkeHUh?=
NB13 MmT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUL6UWxyUUN3ME2xNk46Pzh|IN88US=> M1roZnNCVkeHUh?=
MRK-nu-1 NYDydndGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2C2W2lEPTB;MUOuNVk2KM7:TR?= NFfDZYtUSU6JRWK=
MHH-NB-11 NWfyWYNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTF|LkK5NFIh|ryP NF64SXlUSU6JRWK=
KU812 NVe4NHVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTndFZ3UUN3ME2xN{43OTJ2IN88US=> NVPvcGJuW0GQR1XS
TE-12 M4\Rc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXrTWM2OD1zMz62PVk1KM7:TR?= MWjTRW5ITVJ?
NCI-N87 Mom4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofzTWM2OD1zMz63N|Yh|ryP NInhXpFUSU6JRWK=
EB2 Mm\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjnWXUyUUN3ME2xN{45PTB3IN88US=> MWXTRW5ITVJ?
DB M4nwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrHTWM2OD1zMz65PFg2KM7:TR?= MXvTRW5ITVJ?
697 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTF2LkS1NVEh|ryP M3jKO3NCVkeHUh?=
MSTO-211H M1zSPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzH[Wx3UUN3ME2xOE44PDR6IN88US=> NEX4PGdUSU6JRWK=
JVM-2 MljXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknjTWM2OD1zND63O|M2KM7:TR?= NFrCPZhUSU6JRWK=
COLO-824 MnjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTF2Lke5PVQh|ryP NILOdoFUSU6JRWK=
BC-3 Mle2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFz1VpFKSzVyPUG1MlM6QCEQvF2= Ml\SV2FPT0WU
BOKU NFrBNIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkj5TWM2OD1zNT65OlA5KM7:TR?= NGTRPHdUSU6JRWK=
GOTO Mnz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nE[mlEPTB;MU[uPVYyPyEQvF2= M3;oNHNCVkeHUh?=
HCC2157 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIO2V|BKSzVyPUG3MlQ4PTVizszN NHzucnhUSU6JRWK=
LS-1034 MmfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTF5Lk[4NVgh|ryP NF[4SGdUSU6JRWK=
CAL-148 MnXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTF5Lkm3PVYh|ryP NYn2NmlYW0GQR1XS
MOLT-4 M{DUbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfXTWM2OD1zOD64NlA5KM7:TR?= MoLEV2FPT0WU
Daudi M2ToNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\FWmlEPTB;MUiuPVI{OSEQvF2= M17kenNCVkeHUh?=
J-RT3-T3-5 M4fpfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NET1PXlKSzVyPUG5MlQxPjZizszN Mmm2V2FPT0WU
KMOE-2 NVH0OJI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fwW2lEPTB;MUmuOlQ5OiEQvF2= Mk[2V2FPT0WU
HL-60 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTJyLkG5OlUh|ryP M4HrfnNCVkeHUh?=
P31-FUJ NFi1[|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml75TWM2OD1{MD60O|U{KM7:TR?= NWm3OXdSW0GQR1XS
IM-9 NXfHOm5QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXqNIlKSzVyPUKwMlYzOjRizszN MVPTRW5ITVJ?
HDLM-2 MlmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LzNmlEPTB;MkCuPFgzOSEQvF2= NUnReldkW0GQR1XS
NCI-H1304 M1zDNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\HcZNSUUN3ME2yNU4xOzFzIN88US=> NXmwPVE{W0GQR1XS
NCI-H345 M2rVOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnlWZVlUUN3ME2yNU4xPjR|IN88US=> NYLxOpJEW0GQR1XS
RPMI-6666 MnvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTQcW5mUUN3ME2yNU4{PjB{IN88US=> Mlf2V2FPT0WU
GR-ST NYr0VFF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXIWWhXUUN3ME2yNU41OTdizszN MkHSV2FPT0WU
CHP-126 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2X3c2lEPTB;MkGuOlE5OSEQvF2= MYLTRW5ITVJ?
EHEB MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\TUmlEPTB;MkGuOlc{OSEQvF2= MkPiV2FPT0WU
CPC-N MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTJ2LkCyNFEh|ryP MVHTRW5ITVJ?
NB1 MkDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnk[oY1UUN3ME2yOE43QTN7IN88US=> M4jwSXNCVkeHUh?=
LS-123 NVfRdoM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFT3OVBKSzVyPUK0MlkxOTJizszN MYfTRW5ITVJ?
ST486 NGL3O2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;LfZZuUUN3ME2yOU4yOTF|IN88US=> NHT2dmVUSU6JRWK=
NCI-H1963 NUHIcJlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjIfVEzUUN3ME2yOk4xPjJ|IN88US=> M{LO[nNCVkeHUh?=
U-87-MG NHO5dZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfafYVKSzVyPUK2Mlc3PDRizszN NYT1fGNMW0GQR1XS
COR-L279 NUD4OZJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzGTWM2OD1{Nj63PVIzKM7:TR?= NXG0fZY3W0GQR1XS
LU-165 M2XUd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXftTlR[UUN3ME2yPE4xQDZzIN88US=> NGLKNWZUSU6JRWK=
COLO-800 NWDkd5JOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVi3TmlrUUN3ME2yPE4zQTV4IN88US=> M3HLbXNCVkeHUh?=
ETK-1 NGnaUVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;XeGxwUUN3ME2yPE4{PDR4IN88US=> NVflZ5FpW0GQR1XS
LNCaP-Clone-FGC MmHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTjS4p1UUN3ME2yPU46OjhzIN88US=> M37sU3NCVkeHUh?=
SIG-M5 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFO4W4lKSzVyPUOwMlc6PTJizszN NWLrXppTW0GQR1XS
NB6 M{j2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHs[WtVUUN3ME2zNE46PTB|IN88US=> MoTIV2FPT0WU
NCI-H2107 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVqwRmtEUUN3ME2zNU4zOzN6IN88US=> MYHTRW5ITVJ?
SNU-C1 MnGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofsTWM2OD1|MT6zNVI3KM7:TR?= NIj2VpBUSU6JRWK=
JAR MnXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEf6[pZKSzVyPUOxMlM4QTlizszN M{DJR3NCVkeHUh?=
L-363 NYC3To5sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTFTWM2OD1|Mj6yNVQ1KM7:TR?= MWrTRW5ITVJ?
EW-24 Mm\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTN{LkO0O|Qh|ryP MkPMV2FPT0WU
NB69 MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTN|Lk[0OVQh|ryP M33l[HNCVkeHUh?=
EW-13 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4f3U2lEPTB;M{OuPFk3QSEQvF2= MmGwV2FPT0WU
Ramos-2G6-4C10 M{L6RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFX1OWlKSzVyPUO0MlI6QTNizszN M3rOUnNCVkeHUh?=
TE-11 NU\6OZVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTN2LkS4NlIh|ryP NUH2cFVFW0GQR1XS
L-428 M4rLV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmOwTWM2OD1|ND63OVM3KM7:TR?= NUH1[2tRW0GQR1XS
KP-N-YN MoS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLoTWM2OD1|ND65NFU4KM7:TR?= Mn3tV2FPT0WU
CGTH-W-1 NXnLTIFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTN4LkmwOFgh|ryP NHe5cllUSU6JRWK=
K-562 MnzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\wPWlEPTB;M{euNFg3PCEQvF2= MlLRV2FPT0WU
NCI-H1299 Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rGSWlEPTB;M{iuNVYxOyEQvF2= MoOyV2FPT0WU
RCC10RGB MnTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4f3XmlEPTB;M{iuNlA5OyEQvF2= NXThemZMW0GQR1XS
NCI-SNU-16 M3ztb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\ITlk4UUN3ME2zPE42PjV|IN88US=> NGDSfmdUSU6JRWK=
LC-2-ad NUK3bllIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTN7LkSzN|ch|ryP Mm\UV2FPT0WU
MHH-PREB-1 Mm\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTN7LkezPFgh|ryP MVTTRW5ITVJ?
NCI-H64 NUXDO3Y3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXWVpBKSzVyPUSwMlA6PDhizszN NX7YW|g2W0GQR1XS
LB996-RCC M4DuVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPHZod2UUN3ME20NE45PzF4IN88US=> NXuzZ|dLW0GQR1XS
DEL M2Pw[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\UNGlEPTB;NEGuOFQxPSEQvF2= M4S2bnNCVkeHUh?=
MLMA NYHDTGh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorRTWM2OD12MT63OVk2KM7:TR?= NGTjN3hUSU6JRWK=
SBC-1 M2rEfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTR{LkG4NFYh|ryP NGTrUo5USU6JRWK=
MPP-89 M2nBZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfXOIdJUUN3ME20Nk42QDd3IN88US=> NIf3TFRUSU6JRWK=
MV-4-11 M17Zd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4W4[mlEPTB;NEKuPVA3PyEQvF2= NHLPXHZUSU6JRWK=
EoL-1- MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTR2LkG1Olgh|ryP NY\CPIlCW0GQR1XS
CW-2 Ml7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7SRYRKSzVyPUS0Mlg{PDJizszN MmTCV2FPT0WU
HT MkXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLPdItKSzVyPUS1MlcxODdizszN NYXPOYd5W0GQR1XS
SW954 MnrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\QTWM2OD12Nz60NVI5KM7:TR?= MVHTRW5ITVJ?
A3-KAW M2PMOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7IS2dFUUN3ME20PU45ODZzIN88US=> NULINZdkW0GQR1XS
TC-YIK MmS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;4OphNUUN3ME21NE4xOzZ|IN88US=> MnzHV2FPT0WU
SW962 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYi5SG9KUUN3ME21OE45OzV5IN88US=> M4Plb3NCVkeHUh?=
KP-N-RT-BM-1 NY\C[mZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXyTWM2OD13Nj62OlM5KM7:TR?= NHuwfY5USU6JRWK=
NCI-H1395 M3TQ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfTUoRwUUN3ME21PE45OTd{IN88US=> NXjad5JCW0GQR1XS
RPMI-8402 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTV6Lkm1NlYh|ryP NXXFTZY{W0GQR1XS
SCH Ml3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTo[WdTUUN3ME22NE46PjN6IN88US=> NYq0eVh1W0GQR1XS
NCI-H2196 NGXw[XdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn:zTWM2OD14MT6yN|Eh|ryP M3;aWnNCVkeHUh?=
LOXIMVI M4j1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXKWXdIUUN3ME22NU45OjZ4IN88US=> MX\TRW5ITVJ?
TGBC24TKB MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTuVVZLUUN3ME22Nk4yPDlzIN88US=> M320THNCVkeHUh?=
SK-MEL-2 MnnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzDTWM2OD14Mz65PFkzKM7:TR?= NEf6O2RUSU6JRWK=
U-698-M M3jP[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTZ6LkW2PFch|ryP MWPTRW5ITVJ?
NCI-H1522 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTZ7LkCwOFch|ryP M{H0VHNCVkeHUh?=
UACC-812 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHCe5ZKSzVyPU[5MlUzODlizszN MUDTRW5ITVJ?
MHH-CALL-2 MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTdyLkC2JO69VQ>? NFezbm1USU6JRWK=
NB5 NWSxT4ZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jrcmlEPTB;N{CuN|Q3QCEQvF2= MXnTRW5ITVJ?
KARPAS-299 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHkUWNKSzVyPUewMlQ1PDdizszN NV7LWGNGW0GQR1XS
NCI-H1694 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3Sb|lPUUN3ME23NU4xOzJizszN NV:4fGRmW0GQR1XS
NCI-H82 NWDXcHQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;mTYpKSzVyPUexMlk2ODdizszN MoDwV2FPT0WU
SCC-15 NEjrWYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmToTWM2OD15Mj6zOEDPxE1? MWjTRW5ITVJ?
NCI-H1436 NUD4dm9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHETWM2OD15Mj63OFU3KM7:TR?= M3vHZnNCVkeHUh?=
ATN-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\5TWM2OD15ND61NFUh|ryP M4PVWHNCVkeHUh?=
RPMI-8866 NELDXpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfWWmxWUUN3ME23OE44PTB7IN88US=> MUfTRW5ITVJ?
HCC1599 NWHr[ZdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jSemlEPTB;N{SuPFc{OiEQvF2= NGG0cohUSU6JRWK=
NCI-H1155 Mm\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWq4PWd7UUN3ME23OE46OzZ5IN88US=> NYPtNJdIW0GQR1XS
DOHH-2 NED6V5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTd2Lkm1NVQh|ryP NFS4fYpUSU6JRWK=
SK-NEP-1 NVjOcXRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfVXHFDUUN3ME23OU4xPzV2IN88US=> NV3abGFJW0GQR1XS
HCC1187 NXP1d2hoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofYTWM2OD15Nz62NVIzKM7:TR?= M1XrXHNCVkeHUh?=
NCI-H322M MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzRTWM2OD15OD6zO|A6KM7:TR?= MVnTRW5ITVJ?
NCI-H526 M3;lZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTd6LkW4O|ch|ryP NGjk[5hUSU6JRWK=
NCI-H2171 NY[0SXNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTd7LkSxN|Yh|ryP NHXpVI5USU6JRWK=
COLO-668 NGT3UZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPiVGJFUUN3ME24NU42QDh2IN88US=> MYPTRW5ITVJ?
RS4-11 Mnf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LacGlEPTB;OEKuNlUxPSEQvF2= Mmm0V2FPT0WU
NCI-H716 MkDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTh{LkmwO|Uh|ryP Mor3V2FPT0WU
LU-134-A MlvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXxNFNNUUN3ME24N{4yOzVzIN88US=> MmWxV2FPT0WU
RPMI-8226 NYr4WW9XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{D4UmlEPTB;OESuNlExPyEQvF2= NUfNd3F3W0GQR1XS
KY821 M2nZOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTlzLk[1OVEh|ryP MnixV2FPT0WU
ECC4 NIS2N3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3q3dmlEPTB;OUOuPFI3QSEQvF2= MVTTRW5ITVJ?
EW-3 NFTLUINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;2fGlEPTB;OUSuPVA5OSEQvF2= NWTIU|RtW0GQR1XS
NB7 NYHsTngxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInvTo9KSzVyPUm1Mlc4QDZizszN MVrTRW5ITVJ?
NCI-H720 NWHM[4dOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvLXZFnUUN3ME25PE41ODZzIN88US=> NUn4fJlZW0GQR1XS
NCI-H446 M3PHcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\HUmlEPTB;OUmuO|U5QCEQvF2= NIWwVpdUSU6JRWK=
NCI-H889 M4XDfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvicY5KSzVyPUGwOE4zPDJizszN Ml25V2FPT0WU
EW-22 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrSdGxKSzVyPUGwOk4yQSEQvF2= MUfTRW5ITVJ?
BV-173 M3K4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXnXFRKSzVyPUGwPE44OjhizszN MXnTRW5ITVJ?
WSU-NHL MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTFyOT62O|Eh|ryP MYnTRW5ITVJ?
MN-60 NGS1fWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTFyOT62PUDPxE1? MnX4V2FPT0WU
DG-75 NYPuVZlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXFNoN[UUN3ME2xNVMvOzV{IN88US=> Ml\EV2FPT0WU
DMS-79 M2P1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTQTnV{UUN3ME2xNVcvOzh{IN88US=> NYO2NIxlW0GQR1XS
SK-MEL-1 NWm4NZNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{H0Z2lEPTB;MUG4MlAxQSEQvF2= NEf4PXRUSU6JRWK=
DMS-153 NEfrfpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvtRZpwUUN3ME2xNlEvPzR3IN88US=> NHPVXFFUSU6JRWK=
NCI-H510A NVrxRmZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHW4U2NKSzVyPUGyO{4{OiEQvF2= NHXN[2FUSU6JRWK=
BE-13 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1y0ZmlEPTB;MUO0MlA1PCEQvF2= MUDTRW5ITVJ?
KP-N-YS MmDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIKzfndKSzVyPUGzPU44OzZizszN MnrMV2FPT0WU
SUP-T1 M1rXZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILRdJNKSzVyPUG0N{44ODhizszN NUPtdndpW0GQR1XS
EW-12 NVz0XIxIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fqNGlEPTB;MUS0MlY6QSEQvF2= NUnT[GM5W0GQR1XS
NB14 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnqSmxVUUN3ME2xOFcvODh{IN88US=> NYK2VnB5W0GQR1XS
MDA-MB-134-VI MmTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DmOmlEPTB;MUS4MlI3QCEQvF2= NYPP[3NNW0GQR1XS
NCI-H1770 NUHTZo5qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnOcWNKSzVyPUG1Ok4zPzlizszN MWTTRW5ITVJ?
TUR Mn3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\OUVhoUUN3ME2xOlcvQDdizszN M3T2d3NCVkeHUh?=
NCI-H1417 NHyyZ21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4j1R2lEPTB;MUiwMlM{OSEQvF2= NEnZfWdUSU6JRWK=
IMR-5 M33EZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTF6MT61O|Eh|ryP NULac5h4W0GQR1XS
NCI-H226 NX7TXI9CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTFb2NDUUN3ME2xPFgvQDZ4IN88US=> NVPwZ4pRW0GQR1XS
NCI-H187 NH\BdHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHNUmx2UUN3ME2xPVAvODZ2IN88US=> NHjKfnpUSU6JRWK=
SF539 NYKydXJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPrdnBKSzVyPUG5Nk44OjhizszN M2ruRXNCVkeHUh?=
TALL-1 M2fZNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTF7OD6zNFQh|ryP MoiyV2FPT0WU
TE-441-T MkXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTF7OT63N|kh|ryP MmD4V2FPT0WU
REH M17jWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPmTWM2OD1{M{[uOlI3KM7:TR?= NFziV4JUSU6JRWK=
MS-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTJ|OT6xNlEh|ryP M{fjNnNCVkeHUh?=
THP-1 M3jWb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTJ4ND63N|gh|ryP MkXOV2FPT0WU
NCI-H1838 M3H1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LPfmlEPTB;MkexMlQ2PiEQvF2= Mn3tV2FPT0WU
P30-OHK MoPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTJ6Mz64OFch|ryP M{i5cnNCVkeHUh?=
C8166 M4PsSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4npdGlEPTB;M{S1MlM{QCEQvF2= NWrOW|RJW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western Blot
Bcr-Abl; 

PubMed: 26722260     


(C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown.

Ac-histone H3; 

PubMed: 26722260     


(C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown.

Cleaved-caspase3; 

PubMed: 26722260     


(C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown.

Cleaved-PARP; 

PubMed: 26722260     


(C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown.

ASCL1; 

PubMed: 19765735     


MG-132 decreases the levels of ASCL1 and CgA in carcinoid cancer cells. Pulmonary (NCI-H727) (A) carcinoid cancer cells were treated with MG-132 (0 to 4µM) for 48 hours and cell lysates were analyzed by Western blotting for the expression of ASCL1 and CgA. Treatment with MG-132 results in a dose dependent inhibition of the two neuroendocrine tumor markers. Analysis for GAPDH confirmed equal loading.

CgA; 

PubMed: 19765735     


MG-132 decreases the levels of ASCL1 and CgA in carcinoid cancer cells. Pulmonary (NCI-H727) (A) carcinoid cancer cells were treated with MG-132 (0 to 4µM) for 48 hours and cell lysates were analyzed by Western blotting for the expression of ASCL1 and CgA. Treatment with MG-132 results in a dose dependent inhibition of the two neuroendocrine tumor markers. Analysis for GAPDH confirmed equal loading.

Nrf2; 

PubMed: 23604711     


MG-132 stimulates Nrf2 and HO-1 protein expression in HAECs in a time-dependent fashion. Cells were treated with MG-132 (2 μM) for various times (0–24 h), and Nrf2 and HO-1 protein were quantified by scanning densitometry, normalized with respect to β-actin, and expressed relative to those of control cells.

HO-1; 

PubMed: 23604711     


MG-132 stimulates Nrf2 and HO-1 protein expression in HAECs in a time-dependent fashion. Cells were treated with MG-132 (2 μM) for various times (0–24 h), and Nrf2 and HO-1 protein were quantified by scanning densitometry, normalized with respect to β-actin, and expressed relative to those of control cells.

26722260 19765735 23604711
Immunofluorescence
C2GnT-M / NMIIA; 

PubMed: 22525330     


Confocal images of bC2GnT-M and NMIIA in cells treated with DMSO (D) or MG-132 (E).

AGS3 / Vimentin; 

PubMed: 20065032     


COS-7 cells were transfected with wild-type or TPR-modified AGS3 (AGS3-TPR [M1 to E470] or AGS3-GPR [E470 to S650]) in pEGFP-N1. Thirty-six hours after transfection, cells were incubated with MG 132 (10 μM) for 12 h, and then the cells were processed for immunofluorescence microscopy. The images presented are representative of 2 to 10 separate transfections.

Bak; 

PubMed: 20557369     


Proteasome inhibitor induces Bak activation. Cells were treated with either vehicle or MG-132 at 10 µmol/L for 12 hours and were subjected to Bak immunofluorescence study using antiserum specific for the N terminus of Bak. Upon Bak activation, this epitope is no longer masked within the protein and becomes available for antibody binding upon Bak conformational change.

22525330 20065032 20557369
Growth inhibition assay
Apoptosis assay; 

PubMed: 20557369     


LX-2 cells were incubated for 24 hours in the presence of increasing concentrations of MG-132 (0, 2.5, 5, 10 µmol/L) and in the presence of the pan-caspase inhibitor QVD at 5 µmol/L for 24 hours. MG-132 and QVD were prepared in DMSO as a vehicle. All data were expressed as mean ± standard error from three individual experiments. * p < 0.01 (10 µmol/L MG-132 treated cells vs. 10 µmol/L MG-132 plus QVD treated cells)

Cell viability; 

PubMed: 26137056     


The proteasome inhibitor MG-132 significantly decreased the cell viability in EC9706 cells in a dose- and time-dependent manner.

cell proliferation ; 

PubMed: 19765735     


MG-132 significantly inhibits growth of carcinoid tumor cells in vitro. Pulmonary (NCI-H727) and GI (BON) carcinoid tumor cells were treated with MG-132 at the indicated concentrations (0 to 4µM) for up to 6 days and cell viability was measured every 2 days with the MTT assay (P<0.001). The results show that MG-132 leads to the suppression cellular proliferation in NCI-H727 (A) and BON (B) cells. (OD, optical density)

20557369 26137056 19765735
ELISA
IL-8; 

PubMed: 11160671     


ELISA of IL-8 from supernatant of eTat cells. eTat cells were blocked with Hu (2 mM) and released. MG-132 (50 μM) was added at the time of release. The supernatant was collected at 3 h postrelease and analyzed for IL-8 protein using ELISA. The result shown is representative of three independent experiments ± standard deviation. 

IL-1beta; 

PubMed: 22606244     


LPS-primed WT BMDM were incubated in control medium or medium containing 10 ng/ml ricin or 25 µg/ml cycloheximide for 4 h. MG-132 (30 µM) or Bortezimib (0.5 µM) was included as indicated. Secreted IL-1ß was measured by ELISA in triplicate wells.

11160671 22606244
In vivo Administration of MG-132 effectively rescues the expression levels and plasma membrane localization of dystrophin, β-dystroglycan, α-bdystroglycan, and α-sarcoglycan in skeletal muscle fibers from mdx mice, reduces muscle membrane damage, and ameliorates the histopathological signs of muscular dystrophy. [7] MG-132 treatment significantly reduces immobilization-induced skeletal muscle atrophy in mice, by downregulating the muscle-specific ubiquitin ligases atrogin-1/MAFbx and MuRF-1 mRNA. [8]

Protocol

Kinase Assay:

[1]

- Collapse

Measurement of inhibitory activities of MG-132 against 20S proteasome:

The reaction mixture for the 20S proteasome inhibitory assay contains 0.1 M Tris-acetate, pH 7.0, 20S proteasome, MG-132, and 25 μM substrate dissolved in dimethyl sulfoxide in a final volume of 1 mL. After incuba tion at 37 °C for 15 minutes, the reaction is stopped by the addition of 0.1 mL of 10% SDS and 0.9 mL of 0.1M Tris acetate, pH 9.0. The fluorescence of the reaction products is measured. To determine the IC50 against 20S proteasome, various concentrations of MG-132 are included in the assay mixture.
Cell Research:

[3]

- Collapse
  • Cell lines: KIM-2, HC11, and ES
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 24 and 48 hours
  • Method:

    Cells are exposed to various concentrations of MG-132 for 24, and 48 hours. Supernatant and monolayer cells are harvested by centrifugation and fixed in 70% ethanol in PBS for staining with acridine orange. Equal volumes of cells and acridine orange (5 mg/mL in PBS) are mixed on a microscope slide and examined by fluorescence microscopy. For annexin V analysis, cells are harvested by centrifugation and stained with annexin V and propidium iodide. For cell cycle analysis, cells are rehydrated in PBS at room temperature for 10 minutes, followed by staining with propidium iodide (5 mg/mL). All samples are analyzed using a Coulter Epics XL flow cytometer.


    (Only for Reference)
Animal Research:

[7]

- Collapse
  • Animal Models: Male mdx (C57BL/10ScSn DMD mdx) mice
  • Formulation: Dissolved in DMSO, and diluted in PBS
  • Dosages: ~10 μg/kg/day
  • Administration: Injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 90 mg/mL (189.22 mM)
Ethanol 25 mg/mL (52.56 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+20% propylene glycol+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 475.62
Formula

C26H41N3O5

CAS No. 133407-82-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to know whether it contains EDTA or other chelating agent in this product(S2619)?

  • Answer:

    Our S2619 MG-132 doesn't contain EDTA or other chelating agent.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products

Tags: buy MG-132 | MG-132 supplier | purchase MG-132 | MG-132 cost | MG-132 manufacturer | order MG-132 | MG-132 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID